ASCO 2024 Highlights
Robert F. Siegmund, PhD MBA
BioPharma | Insights & Analytics | AI & Data Science | Forecasting | Strategic Planning | Commercial Strategy
Lung Cancer
Lung cancer research at ASCO 2024 continued to show promising developments, particularly in the treatment of various stages and mutations:
- MARIPOSA Trial: A combination of amivantamab and lazertinib reduced the risk of disease progression or death by 51% in patients with specific EGFR mutations.
- ADRIATIC Trial: Durvalumab was studied for its efficacy as a new consolidation therapy in limited-stage small cell lung cancer, showing substantial improvements in survival rates and highlighting its potential to change the standard of care.
- LAURA Trial: Osimertinib indicated significant improvement in mPFS, setting a new standard for care in unresectable stage III EGFR-mutated lung cancer.
- CROWN Trial: Lorlatinib displayed a 5-year PFS benefit over crizotinib, suggesting its potential as a first-line treatment.
- Rybrevant (Amivantamab) Combo: Improved progression-free survival in refractory EGFR+ NSCLC compared to IV administration.
Breast Cancer
The congress highlighted significant breakthroughs in the treatment of breast cancer, especially focusing on HER2-low expressions:
- DESTINY-Breast-06 Trial: Enhertu (T-DXd) demonstrated significant PFS benefits, especially in low HER2 expression populations.
- Enhertu (Trastuzumab Deruxtecan): Identified as a potential new standard of care for patients with HER2 low and ultralow metastatic breast cancer following hormone therapy.
Multiple Myeloma
- Sarclisa Showed positive Phase 3 results, differentiating from Darzalex based on depth of response, with a launch planned for 2024.
- Blenrep (Belantamab Mafodotin): Demonstrated efficacy in relapsed/refractory multiple myeloma, potentially setting up a re-entry into the US market.
领英推荐
Chronic Myeloid Leukemia (CML)
- Scemblix (Asciminib): Achieved superior molecular response rates compared to standard TKIs in newly diagnosed CML, supporting its use as a first-line treatment option.
Biosimilars and ADC Challenges
- Biosimilar Challenges for ADC Drugs: Noted difficulties in creating biosimilars for ADCs, specifically regarding achieving the correct drug-antibody ratio and maintaining linker stability.
AI in Oncology
AI continues to make strides in oncology, enhancing diagnosis, treatment personalization, and patient management:
- AI Principles by ASCO: Outlined guiding principles including transparency and equity.
- CT-Imaging-Based Biomarkers and BE-a-PAL: Utilizing AI to predict immunotherapy benefits and automate care referrals, enhancing palliative care.
- National AI-based Nutrition Support: A virtual platform providing much-needed nutritional support, showing high satisfaction and improved quality of life metrics.
? Dr. Robert F. Siegmund, Life Code GmbH, Bottmingen, Switzerland, 13.6.2024
Life Code GmbH contact me at [email protected]